论文部分内容阅读
目的 观察耐多药肺结核 (MDR -PTB)采用胸腺因子D(TFD)辅助治疗疗效。方法 5 0例MDR -PTB患者随机分为两组 :治疗组应用抗痨辅助胸腺因子D 10mg ,隔日 1次 ,肌注。对照组单用化疗药物。结果 疗程结束时 ,治疗组痰菌阴转率 84% ,X线胸片病灶吸收率 88% ,空洞闭合率 39 2 9% ,明显高于对照组P <0 .0 5 ;经 2年随访 ,治疗组与对照组细菌学复发率分别为 9 5 %和 5 0 % ,两组之间差异有显著性 (P <0 .0 5 )。结论 胸腺因子D辅助治疗肺结核有一定价值
Objective To observe the efficacy of thymus factor D (TFD) in the treatment of multidrug-resistant pulmonary tuberculosis (MDR-PTB). Methods Fifty cases of MDR-PTB were randomly divided into two groups: the treatment group received anti-tuberculosis thymus factor D 10mg, every other day, intramuscular injection. Control group chemotherapy alone. Results At the end of the course of treatment, the sputum negative conversion rate was 84% in the treatment group, 88% of the X-ray lesions were collected, and the void closure rate was 39 2 9%, significantly higher than that of the control group (P <0.05) The bacteriological recurrence rates of the treatment group and the control group were 95% and 50% respectively, with significant difference between the two groups (P <0.05). Conclusion Thymus D adjuvant treatment of tuberculosis has a certain value